

From BIOTREE to ZETA Biosystem: An Exciting Transition for India's Biopharmaceutical Industry

BIOTREE, a leading biopharmaceutical engineering and process equipment company in India, has rebranded as ZETA Biosystem. This change strengthens the company's integration into the international ZETA Group and the expansion of its services to become a global end-to-end solution provider. Customers can now benefit from their new state-of-the-art Experience Centre in Bengaluru, India.

BIOTREE had established itself as an end-to-end solution provider for Asia's biopharmaceutical industry, offering design, construction, automation, digitalization, and qualification services for customer-specific biopharmaceutical systems for over a decade. The strategic rebranding of ZETA Biosystem aims to improve its integration into the international ZETA Group, allowing the company to access a wide range of resources and expertise.

New training facility “EXPERIENCE CENTRE” to enrich the biopharmaceutical community

With the launch of the Experience Centre in Bengaluru, ZETA Biosystem takes a step forward to build human capital and nurture talent for the biopharmaceutical community. The training center program is delivered by experts to train participants in a cleanroom learning environment with hands-on training to operate process equipment manually and in automatic modes under controlled conditions. The program is designed to educate industry aspirants, graduates, and personnel from within the ZETA Group as well as its customers.

“ZETA Biosystem aims to foster innovation in the biopharmaceutical industry by dedicating itself to quality and precision. Our services will continue to offer reliable, precise, and high-quality engineering solutions in accordance with regulatory compliance”, says Dr. Anil Paul Kariath, CEO of ZETA Biosystem.

Fast execution times for pharma projects globally

ZETA Group is known for managing high-complexity EPCMV pharma projects worldwide and reducing interfaces between the planning and construction of the process system, cleanroom design, and technical building infrastructure. “This unique design-build approach allows for faster execution times, creating value for our customers with quicker market introduction of vital active ingredients”, states Andreas Marchler, CEO of the ZETA Group.

"It's critical to offer customers the same expertise and high-quality solutions regardless of their location. This partnership allows us to do just that”, states Dr. Anil Paul Kariath. "By pooling our resources and skills, we can consistently provide end-to-end solutions globally, from engineering and construction to automation, digitization, and qualification”, concludes Andreas Marchler.

PRESS ZETA Group
Andreas Pompenig
Team Leader Communication
+43 (664) 808 52 1424
andreas.pompenig@zeta.com

PRESS ZETA Biosystem
Ms. Rinu Kariath
Executive Assistant to Board
+91 8095616206
rinu@zetabiosystem.com

About ZETA

The ZETA Group is an end-to-end solution provider operating globally and specializing in the design, construction, automation, digitalization and qualification of customer-specific biopharmaceutical systems for aseptic process solutions.

As general planner, ZETA manages major, high-complexity EPCMV pharma projects and specifically reduces interfaces—from the planning and construction of the process system through the cleanroom design up to the technical building infrastructure. This design-build approach accelerates the project execution time by up to 50% and leads to creation of value earlier in the customer's CAPEX projects. In doing so, ZETA provides an active contribution to the rapid market introduction of vital active ingredients and patients benefit from earlier availability of pharmaceuticals such as anti-cancer medications, insulin and vaccines.

In the field of digitization, ZETA's fully integrated digital value chain—from engineering through qualification and operator management—has established the company as an innovation driver in the pharma and biotech industry. ZETA is also actively taking steps towards a more sustainable future for the entire industry: Holistic decarbonization strategies that reduce targeted emissions during the biopharmaceutical manufacturing process are integrated with sustainable energy sources for the power supply of the entire infrastructure and investment scenarios in renewable energy are evaluated using profitability calculations.

Images

Image credits: Reprint with ZETA copyright notice free of charge



Andreas Marchler, CEO ZETA Group



Dr. Anil Paul Kariath, CEO ZETA Biosystem